Legeartis Poradnie Specjalistyczne Sp. z o.o.

The centre is conducting studies that focus on cardiovascular outcomes in patients with type 2 diabetes, aiming to evaluate how new therapies influence heart‑related events.

• Evaluation of major adverse cardiovascular events with innovative glucose‑lowering agents
• Comparison of treatment safety and effectiveness against standard care
• Assessment of non‑inferiority and potential superiority in reducing cardiovascular risk

These investigations support Legeartis Poradnie Specjalistyczne in advancing care for high‑risk diabetic patients.

Research at the site targets obesity and overweight conditions, exploring how novel compounds can promote weight loss and improve metabolic health.

• Weight reduction efficacy compared with placebo
• Impact on glycemic control in type 2 diabetes
• Long‑term safety and tolerability of emerging agents

The work aligns with broader efforts to address the growing burden of metabolic disease in Poland.